Oral semaglutide was superior to placebo in reducing the risk of major adverse cardiovascular events, researchers reported in the SOUL trial involving over 9,600 adults with high-risk type 2 diabetes.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
A large U.K. trial found that routine use of cerebral embolic protection did not decrease the incidence of stroke within 72 hours among patients undergoing TAVI.
New research links high levels of micronanoplastics in carotid artery plaque to stroke symptoms, suggesting a potential new target for cardiovascular disease prevention.
Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.
"Greater cumulative CVH and improvement in CVH during young adulthood, as well as better CVH in middle age, were all independently associated with lower risk for incident CVD in midlife."